Surgery Partners(US:SGRY) Globenewswireยท2025-11-10 12:30Core Insights - Surgery Partners, Inc. reported a 6.6% increase in revenues for Q3 2025, reaching $821.5 million compared to $770.4 million in Q3 2024, with same-facility revenues up 6.3% [3][4] - The company adjusted its full-year 2025 revenue guidance to a range of $3.275 billion to $3.30 billion and Adjusted EBITDA guidance to $535 million to $540 million, reflecting a cautious outlook due to softer volume and payor mix trends [2][4] - Adjusted EBITDA for Q3 2025 was $136.4 million, a 6.1% increase from $128.6 million in Q3 2024, indicating operational resilience despite challenges [3][7] Financial Performance - Year-to-date revenues for 2025 increased by 7.7% to $2,423.7 million compared to $2,249.9 million in the same period of 2024, with same-facility revenues up 5.4% [4][6] - The company reported a net loss attributable to Surgery Partners, Inc. of $22.7 million for Q3 2025, an improvement from a loss of $31.7 million in Q3 2024 [7][19] - Operating cash flows for Q3 2025 were $83.6 million, up from $65.2 million in Q3 2024, driven by operational growth and reduced transaction-related costs [5][6] Operational Metrics - The number of surgical cases increased by 2.1% in Q3 2025, with same-facility cases rising by 3.4% [7][25] - Revenue per case for Q3 2025 was $4,946, reflecting a 2.8% increase from the previous year [25][27] - As of September 30, 2025, Surgery Partners operated 165 surgical facilities, maintaining the same number as the previous year [25][21] Liquidity and Debt - As of September 30, 2025, the company had cash and cash equivalents of $203.4 million and $405.9 million in borrowing capacity under its revolving credit facility [5][21] - The ratio of total net debt to EBITDA was approximately 4.2x at the end of Q3 2025, indicating a stable leverage position [8][21]